R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AstraZenecaAZ

AstraZeneca Plans Tripled R&D Investment in China, Aims for 15 New Drugs by 2030

CancerSpecial review status

CDE Issues Guidelines on Single-Arm Clinical Trials for Antitumor Drugs

AIDP Technology

XtalPi and DP Technology Partner to Accelerate Pre-Clinical Drug Development with AI

Pasteur Institute Suspends Joint Venture with Chinese Academy of Sciences

Show More